Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00720759 · ClinicalTrials.gov registry record · Phase 2
Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine
A Phase 2 study, sponsored by US Department of Veterans Affairs.
- Completed
- Registry status
- Phase 2
- Development phase
- 24
- Enrollment target
NCT00720759: Completed Phase 2 study, sponsored by US Department of Veterans Affairs.
NCT00720759 is a Phase 2 study that has completed, run by US Department of Veterans Affairs. The registered enrollment target is 24 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00720759, a Phase 2 study, has completed, sponsored by US Department of Veterans Affairs.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 24 participants
- Enrollment target
Study Summary
Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be effective in improving arm function. However, for most subjects, improvement is modest. In this trial, we test two approaches that may increase the amount of improvement achieved: 1) distributing treatment over a greater amount of time; and 2) adding a drug, d-cycloserine, which theoretically enhances the molecular mechanisms of learning.
Primary Outcome
The Wolf Motor Function Test (time) score is the average time in seconds taken to perform each of 15 functional tasks ranging in difficulty from putting one's forearm on a table to stacking checkers. Participants are given 120 seconds to perform a task and if they fail, they are scored 120 for that task. Score range on the WMFT-T is 0-120, lower scores being better.
Interventions
- DRUG D-cycloserine + distributed treatment
- BEHAVIORAL D-cycloserine + condensed treatment
- DRUG Placebo + distributed treatment
- BEHAVIORAL Placebo + condensed treatment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
What the finished NCT00720759 record still lists
NCT00720759 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (82% lower).
The record links to 0 conditions, and to 4 interventions - of which D-cycloserine + distributed treatment is the first listed.
NCT00720759 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00720759 about?
NCT00720759 is a clinical study titled "Improving Stroke Rehabilitation: Spacing Effect and D-cycloserine". Each year 730,000 Americans experience a stroke. Forty percent are left with significant paralysis of one arm. Certain types of physical therapy, for example constraint induced movement therapy (CIMT), have been shown to be effective in improving arm function. However, for most subjects, improvement...
What is the current status of trial NCT00720759?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2009-07. Estimated completion is 2011-11.
What interventions are being tested in trial NCT00720759?
The interventions under investigation include: D-cycloserine + distributed treatment (DRUG), D-cycloserine + condensed treatment (BEHAVIORAL), Placebo + distributed treatment (DRUG), Placebo + condensed treatment (BEHAVIORAL).
Who is sponsoring clinical trial NCT00720759?
This trial is sponsored by US Department of Veterans Affairs, which has 632 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00720759's enrollment target sits among peer trials
24 1756th of 2000 higher than 217 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia